Evidence map›Paper›PMID 27644195›Full record

ArticleMolecular and cellular biochemistry2016

Involvement of microRNA-141-3p in 5-fluorouracil and oxaliplatin chemo-resistance in esophageal cancer cells via regulation of PTEN.

Ying-Ying Jin, Qing-Juan Chen, Kun Xu, Hong-Tao Ren, Xing Bao, Yi-Nan Ma, Yang Wei, Hong Bing Ma

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.

  1. Pooled it
  2. The cross-talk between GSK-3β, RKIP, and PTEN as potential targets for therapeutic implications in cancer: a comprehensive insight.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Cancer resistance via the downregulation of the tumor suppressorsExploration of targeted anti-tumor therapy · 2023
    Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Ying-Ying JinDepartment of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, No. 157, Xiwulu, Xi'an, 710004, Shaanxi, China.
Qing-Juan ChenDepartment of Oncology, Xian Yang Center Hospital, Xian Yang, 610041, Shaanxi, China.
Kun XuDepartment of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, No. 157, Xiwulu, Xi'an, 710004, Shaanxi, China.
Hong-Tao RenDepartment of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, No. 157, Xiwulu, Xi'an, 710004, Shaanxi, China.
Xing BaoDepartment of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, No. 157, Xiwulu, Xi'an, 710004, Shaanxi, China.
Yi-Nan MaDepartment of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, No. 157, Xiwulu, Xi'an, 710004, Shaanxi, China.
Yang WeiScientific Research Center, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710004, Shaanxi, China.
Hong Bing MaDepartment of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, No. 157, Xiwulu, Xi'an, 710004, Shaanxi, China. mhbxian@sina.com.
Second Affiliated Hospital of Xi'an Jiaotong University · CNXian Yang Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

microRNAs (miRNAs) act as a major regulator of acquired chemo-resistance in various types of cancer therapeutics. This study investigated the contribution of miRNAs in influencing multiple drug resistance in esophageal squamous cell carcinoma (ESCC). The sensitivity of four ESCC cell lines (EC109, EC9706, TE-1 and KYSE-150) to 5-fluorouracil (5-FU) and oxaliplatin (OX) was determined by MTT assay. A 5-FU and OX-resistant subline, EC9706R, was established by continuous exposure to stepwise increasing concentration of 5-FU and OX. Microarray technology was used to compare the differential expression of miRNAs between resistant cells and parental cells. Chemo-sensitivity assay was performed to evaluate drug response in EC9706R cells transfected with miRNA mimic or inhibitor. The direct targets of miRNA were identified by employing pathway analysis and then confirmed with luciferase assay. Sixty ESCC tissue samples and their paired adjacent normal tissues were collected to validate the expression of identified miRNA. Mouse models were further utilized to investigate the function of miRNA on acquired chemo-resistance. MicroRNA panel results indicated that a total of 12 miRNAs were differentially expressed and miR-141-3p was highly over expressed in resistant cells. Inhibition of miR-141-3p reversed acquired chemo-resistance in EC9706R cells by stimulating apoptosis. The expression of miR-141-3p was significantly increased in ESCC tissue samples compared to their matched distant normal tissues. In addition, the elevated miR-141-3p expression was found to be associated with ESCC differentiation status and TNM stage. Moreover, Phosphatase and tensin homolog (PTEN) was identified as direct target of miR-141-3p. Western blot exhibited altered protein levels of PTEN, Akt, and PI3k with miR-141-3p inhibitor. An inverse correlation between PTEN expression and miR-141-3p expression was also observed in tissue samples. EC9706R xenograft mouse model became sensitized to 5-FU and OX treatment following miR-141-3p inhibitor transfection in vivo. Our study demonstrated that miR-141-3p contributed to an acquired chemo-resistance through PTEN modulation both in vitro and in vivo.

Indexed as

Drug Resistance, NeoplasmAnimalsEsophageal NeoplasmsFemaleFluorouracilGene Expression Regulation, EnzymologicGene Expression Regulation, NeoplasticHumansMaleMiceMicroRNAsNeoplasm ProteinsOrganoplatinum CompoundsOxaliplatinPTEN PhosphohydrolaseRNA, NeoplasmFluorouracilMicroRNAsMIRN141 microRNA, humanNeoplasm ProteinsOrganoplatinum CompoundsOxaliplatinPTEN PhosphohydrolasePTEN protein, humanRNA, NeoplasmCell lineChemotherapyEsophageal squamous cell carcinomamicroRNAResistanceXenograft

Identifiers

PMID27644195
OpenAlexW2522309607

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.